Beta Bionics CCO sells 36,870 shares at $18.46

Beta Bionics’ chief commercial officer reported a Rule 10b5-1 plan stock sale totaling 36,870 shares, leaving him with 87,157 shares.

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) disclosed that Chief Commercial Officer Mark Hopman sold 36,870 shares of common stock on September 9, 2026 in an open market or private transaction at an average price of $18.4628 per share. The transaction was executed pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026, and Hopman now directly holds 87,157 shares of Beta Bionics common stock.

Insider Trade Summary 10b5-1

Net Seller: 36,870 shares

Net Sell 1 txn

Insider Hopman Mark

Role Chief Commercial Officer

Sold 36,870 shs ($681K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	36,870	$18.4628	$681K

Holdings After Transaction: Common Stock — 87,157 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.

Key Figures

Shares sold: 36,870 shares Average sale price: $18.4628 per share Shares held after transaction: 87,157 shares +1 more

4 metrics

Shares sold 36,870 shares Common stock sold by Chief Commercial Officer on September 9, 2026

Average sale price $18.4628 per share Price for the 36,870 common shares sold on September 9, 2026

Shares held after transaction 87,157 shares Direct common stock ownership by Chief Commercial Officer after the sale

Net shares sold 36,870 shares Net share change from reported non-derivative transactions in this filing

Key Terms

Rule 10b5-1 Plan, open market or private transaction

2 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open market or private transaction financial

"The transaction is described as a sale in an open market or private transaction."

FAQ

What insider transaction did BBNX report for Chief Commercial Officer Mark Hopman?

Beta Bionics reported that Chief Commercial Officer Mark Hopman sold 36,870 shares of common stock on September 9, 2026 in an open market or private transaction at an average price of $18.4628 per share.

How many BBNX shares does Mark Hopman hold after the reported sale?

After the reported sale, Chief Commercial Officer Mark Hopman directly holds 87,157 shares of Beta Bionics common stock. This figure is stated as his direct ownership immediately following the September 9, 2026 transaction.

Was the BBNX insider sale by Mark Hopman under a Rule 10b5-1 trading plan?

Yes. The filing states that the 36,870 shares sold on September 9, 2026 were sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026, indicating the trades were made under a pre-arranged trading plan.

What was the average sale price for Mark Hopman’s BBNX shares?

The sale by Chief Commercial Officer Mark Hopman was executed at an average price of $18.4628 per share for the 36,870 shares of Beta Bionics common stock sold on September 9, 2026.

Does the Form 4 for BBNX indicate multiple insider transactions or just one?

The Form 4 reports one non-derivative transaction for Chief Commercial Officer Mark Hopman: the sale of 36,870 shares of Beta Bionics common stock on September 9, 2026 in an open market or private transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:31 PM Accepted by SEC EDGAR 09/10/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2026		S(1)		36,870	D	$18.4628	87,157	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.

	/s/ Stephen Feider, Attorney-in-Fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)